Ophthalmology
February 21, 2012
Dame Judi Dench Among Millions With Macular Degeneration
Dame Judi Dench, the actress who plays the steely-eyed boss keeping watch over James Bond, revealed she is losing her sight to macular degeneration… “People with a family history of macular degeneration have a higher risk,” said Dr. Sophie Bakri, professor of ophthalmology at the Mayo Clinic in Rochester, Minn. Dench revealed that her mother, […]
Tags: Dame Judi Dench, Dr. Sophie Bakri, James Bond, macular degeneration
January 25, 2012
Heard on the Street: Mayo Clinic eyes $5.3 million remodel project
It looks like Mayo Clinic has another major remodeling project — with a $5.3 million price tag — in its sights for downtown Rochester. Mayo applied for a building permit last week to remodel the fourth and seventh floors of the Mayo Building at 200 First St. S.W. The work will benefit the ophthalmology department, […]
January 19, 2012
Mayo Clinic Medical Edge: Cataract surgery is possible for most people who’ve had LASIK,
DEAR MAYO CLINIC: Is it true that I can’t have cataract surgery because I once had LASIK? I’m only 57 and am worried about losing my eyesight. ANSWER: No, that’s not true. Successful cataract surgery is possible for most people who have had laser-assisted in-situ keratomileusis (LASIK surgery) or other types of refractive surgery that […]
January 19, 2012
Potential Treatment for Degenerative Eye Diseases Developed at Wayne State
Former Wayne State University opthalmology researchers Raymond Iezzi and Rangaramanujam Kannan have developed a new way to treat age-related macular degeneration and retinitis pigmentosa using injections of nanoparticles, the university announced earlier this month. Iezzi, who has since gone on to the Mayo Clinic, and Kannan, who is now with Johns Hopkins, are currently in the […]
January 17, 2012
Treating Macular Degeneration: Nanoparticle-Delivered Steroids,
A collaboration of researchers from Wayne State University, the Mayo Clinic, and Johns Hopkins Medicine has discovered a potential new treatment for macular degeneration and retinitis pigmentosa. The investigators managed to attach steroids to dendrimers nanoparticles and show that the drugs only targeted the activated microglia, the damage-causing cells associated with neuroinflammation… Here’s a video […]
January 17, 2012
Younger children are more responsive to amblyopia treatment
Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years, according to a study featured in Archives of Ophthalmology. Dr Jonathon M. Holmes and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, performed a meta-analysis of 4 recently completed randomized amblyopia treatment. This […]
January 17, 2012
Dry age-related macular degeneration and retinitis pigmentosa are caused by neuroinflammation, which progressively damages the retina and can lead to blindness. Macular degeneration is the primary cause of vision loss in older Americans, affecting more than 7 million people, according to the National Institutes of Health. Retinitis pigmentosa encompasses many genetic conditions affecting the retina […]
January 17, 2012
Nanoparticles Help Researchers Deliver Steroids to Retina
Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A collaborative research study among investigators at Wayne State University, the Mayo Clinic and Johns Hopkins Medicine shows that steroids attached to the dendrimers targeted the damage-causing cells associated with neuroinflammation, leaving the […]
December 23, 2011
Potential Treatment for Degenerative Eye Diseases Developed at Wayne State
Former Wayne State University opthalmology researchers Raymond Iezzi and Rangaramanujam Kannan have developed a new way to treat age-related macular degeneration and retinitis pigmentosa using injections of nanoparticles, the university announced earlier this month. Iezzi, who has since gone on to the Mayo Clinic, and Kannan, who is now with Johns Hopkins, are currently in the […]
Tags: opthalmology, Raymond Iezzi
November 1, 2011
Oxford BioMedica signs glaucoma pact with Mayo Clinic
Oxford BioMedica of the UK has linked up with the USA’s renowned Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma…The pact builds on earlier pre-clinical research, conducted by Mayo Clinic which has established initial proof-of-concept for this approach to treating chronic glaucoma. PharmaTimes, Kevin Grogan, 11/1/11 Additional coverage: Pharmaceutical Business […]